QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
NASDAQ:CYAD

Celyad Oncology (CYAD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.40
$0.65
50-Day Range
$0.59
$0.85
52-Week Range
$0.46
$3.07
Volume
3,009 shs
Average Volume
N/A
Market Capitalization
$15.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CYAD stock logo

About Celyad Oncology Stock (NASDAQ:CYAD)

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.


CYAD Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Celyad Announces Management Change
Celyad Oncology Share Price (CYAD.BR)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Celyad Oncology to Terminate ADR Program
Celyad Oncology SA (CYAD.BR)
Celyad Oncology (CYADY) Earnings Dates & Reports
Celyad Oncology SA (CYADY)
See More Headlines
Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/21/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAD
Employees
95
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.20 per share

Miscellaneous

Free Float
26,276,000
Market Cap
$15.91 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Georges Rawadi
    Chief Executive Officer & Executive Director
  • David Georges
    Vice President-Finance & Administration
  • Eytan Breman
    Director-Research & Development
  • An Phan
    Head-Legal














CYAD Stock Analysis - Frequently Asked Questions

When is Celyad Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our CYAD earnings forecast
.

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

This page (NASDAQ:CYAD) was last updated on 2/21/2024 by MarketBeat.com Staff